EP1924685A2 - Modèle de carcinogenèse par fusion de cellules souches - Google Patents

Modèle de carcinogenèse par fusion de cellules souches

Info

Publication number
EP1924685A2
EP1924685A2 EP06802407A EP06802407A EP1924685A2 EP 1924685 A2 EP1924685 A2 EP 1924685A2 EP 06802407 A EP06802407 A EP 06802407A EP 06802407 A EP06802407 A EP 06802407A EP 1924685 A2 EP1924685 A2 EP 1924685A2
Authority
EP
European Patent Office
Prior art keywords
cell
cells
tumor
fusion
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06802407A
Other languages
German (de)
English (en)
Other versions
EP1924685B1 (fr
EP1924685A4 (fr
Inventor
David T. Harris
Tom C. Tsang
Xianghui He
Brian L. Pipes
Linda C. Meade-Tollin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizona Board of Regents of University of Arizona
University of Arizona
Original Assignee
Arizona Board of Regents of University of Arizona
University of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizona Board of Regents of University of Arizona, University of Arizona filed Critical Arizona Board of Regents of University of Arizona
Priority to EP11165870.4A priority Critical patent/EP2363146B1/fr
Publication of EP1924685A2 publication Critical patent/EP1924685A2/fr
Publication of EP1924685A4 publication Critical patent/EP1924685A4/fr
Application granted granted Critical
Publication of EP1924685B1 publication Critical patent/EP1924685B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Definitions

  • the invention relates to a cell system and method for modeling, screening drugs against, and inhibiting migration of cancer cells.
  • Cancer has been difficult to treat because of tissue heterogeneity and gene instability.
  • cancer was described as early as 1600 B.C. in ancient Egyptian writings. Hippocrates, the ancient Greek physician, recognized the difference between benign and malignant tumors and named malignant tumors "carcinos.” Cancer is currently the second-leading cause of death in developed countries.
  • stem cell theory of carcinogenesis has gained momentum with insights gained from stem cell research and the discovery of “cancer stem cells.”
  • the stem cell theory of carcinogenesis suggests that stem cells accumulate genetic mutations and become malignant cells.
  • the stem cell theory cannot fully address what causes the distinctive features of cancer, such as invasion and metastasis.
  • Genomic instability was proposed as the enabling characteristic of the hallmarks of cancer. As the phenotype of genomic instability, aneuploidy has been observed in nearly all solid human cancers and is difficult to explain with gene mutation hypothesis. It has been proposed that aneuploidy accounts for cancer as an autonomous mutator, but the mechanism underlying aneuploidy remains unclear.
  • cancer can result from a fusion between an "altered" pre-malignant cell and a bone marrow-derived stem cell (BMDSC).
  • BMDSC bone marrow-derived stem cell
  • Aneuploidy which is a hallmark of malignancy, is a direct consequence of this cell fusion.
  • the "stem cell fusion” model explains the remarkable similarities between malignant cells and BMDSC. This model also explains why non-mutagens can be carcinogens, and why non-mutagenic processes, such as wound healing and chronic inflammation, can promote malignant transformation.
  • a method for modeling cancer cell migration preferably includes providing a bone marrow derived stem cell, providing a genetically altered cell, fusing the bone marrow derived stem cell with the genetically altered cell, thereby creating a fused cell; and measuring an indicator of migration for the fused cell.
  • the method may obtain or culture the fused cell from a previous fusion of the bone marrow derived stem cell with the genetically altered cell.
  • a method for screening an effect of a biological or chemical agent on tumor cell migration includes providing a fused cell derived from a fusion of a bone marrow derived stem cell with a genetically altered cell, contacting the fused cell with a biological or chemical agent, and determining whether tumor cell migration is promoted, inhibited, or unchanged.
  • a method for inhibiting tumor cell migration includes comprising contacting a tumor cell with an effective amount of an antibody against ubiquitin.
  • this antibody is MEL- 14, [e.g., MEL-14-F(ab') 2 ], antibody 14372 or antibody 10C2-2.
  • the methods of the invention represent a new and improved carcinogenesis model for in vitro studies of tumor cell migration and in vivo studies using animals with transplanted with marker-gene modified bone marrow, for example, eGFP transgeneics. Additional features and advantages of the invention will be forthcoming from the following detailed description of certain specific embodiments when read in conjunction with the accompanying drawings.
  • FIG. 1 is a schematic illustration of malignant transformation mediated by fusion between bone marrow derived stem cells and "altered" tissue cells.
  • a “metastasis” means the spread of cancer from one part of the body to another.
  • a tumor formed by cells that have spread is called a “metastatic tumor” or a “metastasis.”
  • malignant means cancerous, i.e., abnormal cells that divide without control and that can invade nearby tissues and spread through the bloodstream and lymphatic system to other parts of the body.
  • altered cell or "genetically altered cell” are defined here as any cells with genetic or epigenetic changes sufficient to skew the normal differentiation pathway of a bone marrow derived stem cell after fusion with a BMDSC.
  • altered cells include so-called “initiated” (pre-malignant) cells in the multiple-step carcinogenesis model.
  • fusion cell means a cell formed by the fusion of an altered cell and a bone marrow derived stem cell.
  • BMDSC bone marrow-derived stem cells
  • Figure 1 Purified BMDSC populations are obtained by removing all bone marrow derived cells that expressed a differentiated cell surface markers using commercially available columns. The lineage negative cells that passes through the columns can be further enriched for stem cells by positively selecting for CD34 positive, CD 133 positive and SCA-I positive cells. This works for both mouse and human BMDSC.
  • the invention relates in part to the recognition that the fusion between "altered" tissue cells with BMDSC may result in malignant transformation of the hybrid cells.
  • so-called “initiated” cells in multiple step carcinogenesis model and benign tumor cells can be given the ability to migrate.
  • the normal differentiation pathway of BMDSC could be disrupted due to the existing genetic or epigenetic disorder of the "altered" tissue cells.
  • Genetic disorders could be gene mutations, translocations, deletions, or amplifications as proposed by the gene mutation hypothesis.
  • Epigenetic disorders could be any change beyond the DNA sequences that result in dysregulation of cell growth and function, such as DNA methylation, chromatin modification, or altered cellular signaling. Fusion could give rise to daughter cells with the phenotype of both: the altered cells and BMDSC. In other words, the daughter cells could acquire the capability of self-renewal, tissue invasion and migration from BMDSC, thereby turning into malignant cells.
  • fusion process subsequent mitosis and loss of individual copies of chromosomes, will result in aneuploidy.
  • Aneuploidy could become the driving force of genomic instability and cancer progression.
  • a single fusion event could have the same transforming (from benign to malignant) effect as that of multiple events involved in the process of classical multistage carcinogenesis.
  • BMDSC are highly plastic.
  • bone marrow not only contains hematopoietic stem cells (HSC), but also contains mesenchymal stem cells (MSC), endothelial cell progenitors, and stem cells of epithelial tissues that can differentiate into epithelial cells of liver, lung, skin, and gastrointestinal tract.
  • HSC hematopoietic stem cells
  • MSC mesenchymal stem cells
  • endothelial cell progenitors stem cells of epithelial tissues that can differentiate into epithelial cells of liver, lung, skin, and gastrointestinal tract.
  • Chemokine receptors such as CXCR4 CXCR4 expressed in metastatic tumor
  • Wnt and Hedgehog signal activity Wnt and Hedgehog signal activity
  • BMDSC and metastatic cancer cells are capable of self-renewal, migration, and tissue invasion.
  • Certain cancer cells express purported stem cell markers.
  • c-kit is strongly expressed in serous ovarian carcinoma, testicular carcinoma, malignant melanoma, and small cell lung carcinoma.
  • CD34 is expressed in dermatof ⁇ brosarcoma, epitheloid sarcoma, and solitary fibrous tumors.
  • all types of cancer cells acquire telomere maintenance capability, similar to stem cells, which are telomerase positive.
  • BMDSC express particular chemokine receptors and reach their destination by chemokine-ligand interactions.
  • fusion is a fundamental phenomenon in the life of many organisms. Intracellular vesicle fusion is essential for basic cellular function. Enveloped viruses deliver viral capsids into the cytosol through membrane fusion. From yeast to humans, life begins with fusion. Cell-cell fusion is a part of normal biological processes during the development of muscle, bone and placenta. As early as 1911, it has been proposed that malignancy could be a consequence of hybridization between leukocytes and somatic cells.
  • fusion can occur multiple times between normal, pre-malignant and malignant cells; however, the invention specifically involves fusion between an "altered" pre-malignant tissue cell and BMDSC as a crucial step in carcinogenesis. There may be multiple fusions with the BMDSC, thereby leading to at least a tetraploid karyotype after fusion takes place.
  • stem cells After fusion with altered tissue cells, the normal self-renewal and differentiation of stem cells is thought to be disrupted by the abnormal signal derived from the altered cells.
  • the invention is consistent with the studies that show that stem cells are less tolerant to DNA damage than differentiated cells. Stem cells should be more sensitive to DNA damage in order to maintain the multipotent differentiation potential. There is no doubt that BMDSC are more sensitive to radiation than mature cells. This fact is the basis of clinical myeloablation. There is also the observation that tissue stem cells are more sensitive to killing by DNA-damaging agents. Apoptosis levels of intestinal crypt stem cells are markedly elevated by exposure to radiation or cytotoxic agents.
  • tissue cells rather than stem cells, accumulate genetic and epigenetic disorders. After fusion with BMDSC, the daughter cells are transformed and give rise to malignant tumors.
  • Chromosomal abnormalities have been identified as one of the distinctive pathological features of cancer for more than 100 years. Aneuploidy has been observed in nearly all solid human cancers. In addition, clinical data suggest that the degree of aneuploidy is correlated with the severity of the diseases. An aneuploidy hypothesis of cancer emphasized the importance of aneuploidy in carcinogenesis, but the mechanism underlying aneuploidy remains unclear. In the stem cell fusion model of carcinogenesis described here, aneuploidy is an inevitable consequence of cell fusion resulting in loss of individual chromosome copies.
  • Tissues that normally undergo rapid renewal are expected to experience an increased cancer incidence, as a high turnover rate should result in local tissue stem cell exhaustion and infiltration of BMDSC.
  • epithelium in the skin, the lungs, and the gastrointestinal tract which are continuously exposed to environmental insult and constantly in a state of renewal, are the tissues with a high proportion of cancers.
  • the increased engraftment of bone marrow derived keratinocytes during wound healing has been demonstrated in sex-mismatched bone marrow transplanted mice, though the same study ruled out the presence of fusion between bone marrow-derived cells and skin epithelial cells in acute injury.
  • Helicobacter infection is a major attributable factor in the development of gastric cancer. Chronic tissue damage and ongoing tissue repair cause an imbalance between epithelial cell proliferation and apoptosis in the stomach. Indeed, it recently was reported that bone marrow-derived cells are the origin of gastric cancer in Helicobacter-mfected mice.
  • EBV Epstein-Barr virus
  • Burkitt's lymphoma non-Hodgkin's lymphoma
  • Hodgkin's disease Nasopharyngeal carcinoma
  • gastric adenocarcinoma gastric adenocarcinoma
  • EBV induces cell-cell fusion, especially by virus isolated from tumors.
  • the inventor's stem cell fusion model of carcinogenesis could explain why EBV infection associates with so many cancers.
  • the stem cell fusion model of cancer has significant implications for cancer research and drug development, as well as for the therapeutic application of stem cells.
  • Malignant cells might be susceptible to therapies that induce differentiation. Differentiation could switch off self-renewal activity and decrease the capability of malignant cells to metastasize and invade tissues.
  • differentiation-inducing agents such as retinoic acid or peroxisome proliferators- activated receptor-gamma (PP AR ⁇ ) agonists, have been used for the successful treatment of acute myeloid leukemia or liposarcoma, respectively.
  • PP AR ⁇ peroxisome proliferators- activated receptor-gamma
  • Introduction of a differentiation signal into malignant cells through gene transfer might be a novel viable approach for cancer therapy.
  • metastatic cells might have a homing pattern similar to BMDSC; therefore, approaches to block BMDSC homing could be used to inhibit cancer metastasis.
  • a recent study has demonstrated that silencing of the chemokine receptor CXCR4 through RNA interference blocks breast cancer metastasis in mice. Cancer is difficult to control because its genetics are so chaotic.
  • the BMDSC derived malignant characteristics of the cancer cells could present a conserved target for design of new therapies.
  • cancer metastasis would use the same conserved molecular mechanisms as the BMDSC and their progeny that include neutrophils, lymphocytes, and other leukocytes. Therefore, the inventors have examined whether antibodies to ubiquitin, which can block neutrophils, lymphocytes, and other leukocytes' motility and extravasation in vivo, will block cancer cell's motility and extravasation and therefore block metastasis. Furthermore, determining the presence of the of BMDSC/altered cell fusions in tumors could alert the attention of researchers to a possible unintended " consequence of stem cell-based therapy (i.e., improper administration of stem cells might actually increase the incidence of malignancy).
  • a method for modeling cancer cell migration includes the steps of: (a) providing a bone marrow derived stem cell; (b) providing a genetically altered cell; (c) fbsing the bone marrow derived stem cell with the genetically altered cell, thereby creating a fused cell; and (d) measuring an indicator of migration for the fused cell.
  • BMDSC and genetically altered cells are readily available from commercial and academic tissue culture and live sources.
  • cell fusion is routinely practiced such that there are many protocols available (see, for example, the hybridoma protocols at protocol-online.org.).
  • Measuring an indicator of migration for the fused cell (and it progeny) can be done through an in vitro "scratch assay" (e.g., LaI A, Glazer CA, Martinson HM, et al. Cancer Res 2002, 62:3335-3340) or through in vivo animal studies (e.g., injection of tumor cells including one or more fused cells and monitoring metastasis as described in the examples below).
  • scratch assay e.g., LaI A, Glazer CA, Martinson HM, et al. Cancer Res 2002, 62:3335-3340
  • in vivo animal studies e.g., injection of tumor cells including one or more fused cells and monitoring metastasis as described in the examples below.
  • the invention further involves method for screening an effect of a biological or chemical agent on tumor cell migration either in vitro or in vivo.
  • the method includes providing a fused cell derived from a fusion of a bone marrow derived stem cell with a genetically altered_cell; contacting the fused cell with a biological or chemical agent, and determining whether tumor cell migration is promoted, inhibited, or unchanged.
  • conserveed proteins would be an especially good target for screening the effects of agents on migration.
  • Ubiquitin(ub) is the most conserved protein found in nature. Among its sequence of 76 amino acids, there is complete homology between species as evolutionarily divergent as insects, trout, and human. Ubiquitin makes up part of the outer surface domains of several other membrane receptors. In the case of Lymphocyte homing receptors(LHR), the presence of ub is closely correlated to LHR's function in facilitating the binding and migration of Lymphocytes through lymph nodes. All of the receptors that have been shown to be linked to ub have also been known to mediate cellular mobility. A possible explanation of these observations is that ub is involved in mediating cellular mobility through the extracellular matrix.
  • LHR Lymphocyte homing receptors
  • the biological or chemical agent is an antibody against ubiquitin, such as MEL-14 (CD62L) (available through Abeam PIc, Zymed Laboratories, et al.; see abcam.com for 21 different antibodies to ubiquitin).
  • MEL-14 CD62L
  • the cells contacted by this antibody have been subjected to a scratch assay or used in animal experiments to determine the effect of the antibody on cell migration as described below.
  • a method for inhibiting tumor cell migration is described to include contacting a tumor cell with an effective amount of an antibody against ubiquitin.
  • this embodiment includes the step of confirming the presence of a fused cell among the tumor cells prior to contacting the tumor cells with the antibody so that such inhibition can be targeted to tumors with greater malignant potential.
  • One may determine jfthe tumor cell sample contains a cell with at least tetraploid DNA and at least one cell-surface marker specific to a bone marrow derived stem cell.
  • Such surface cell markers include c-kit, CD34 and CD133 and chemokine receptors, such as CXCR.4.
  • the goal of this first study is to test a previously proposed hypothesis for carcinogenesis, in which the interaction of bone marrow derived stem cells and transformed cells can alter tumor progression.
  • Two types of experiments can be performed.
  • cells derived from mouse bone marrow are isolated from mice which transgenically express eGFP and combined with transiently transfected transformed human or mouse cells labeled with Clontech's red fluorescent protein under conditions which facilitate the formation of hybrid cells. These hybrid cells will then be injected into a strain of mice appropriate for the cell line being tested.
  • Alteration of primary or metastatic tumor growth is monitored as a function of time.
  • mice must be used so that the host immune response to the administration of transformed mouse (308, 308 10Gy5, or 4Tl) and human (DU145 or PC-3 M) cell lines, well-established model systems for breast, skin, and prostate cancer, will be minimal.
  • Subcutaneous inoculation or tail vein injection is used to administer mouse cell lines into athymic nude mice.
  • the human cell lines are administered to SCID mice.
  • An aliquot containing cell lines, singly or in combination, are injected on day 0 and tumor growth is followed for a maximum of 40 days. Mice are then be sacrificed, tissues removed, and tumor volume and relative levels of lung metastases quantitated.
  • Heterozygous transgenic eGFP mice [C57BL/6-TgN (ACTbEGFP) 1 Osb] (Jackson Laboratory) are used as a source of GFP labeled bone marrow cells. GFP mice are identified by expression of green fluorescence under UV light. 2- to 4-month old female heterozygotes are used as the donors for the BMT. Donor's gender is different from that of the recipient host.
  • Bone marrow derived cells are obtained from heterozygous GFP mice by flushing the femur and tibia with Hanks' balanced solution. To generate somatic cell hybrids, 10 6 bone marrow-derived cells and 106 tumor cells are plated on 60 mm dishes 24hours before treatment with polyethylene glycol (PEG). 5 grams of PEG with a molecular weight of 3000-3700 is prepared by autoclaving for 5 minutes at 121 degrees C. The autoclaved PEG is then combined with 5 ml of 2x sterile serum-free medium, pre-warmed to 37 C to prepare a 50% solution. One ml of the 50% PEG solution per dish is then added slowly to the co-cultured cells, and the cells are incubated for 1 minute a 137degrees.
  • PEG polyethylene glycol
  • Experiment 2 Altered tumorigenicity and progression of mouse and human benign tumor cells.
  • mice are inoculated with GFP-labeled bone marrow cells, singly or in combination with transformed benign human or mouse cells.
  • Group A 72 mice.
  • Strains Athymic nude mice for 308 cells; SCID for DUl 45 or PC-3 M tumors (Pain category D).
  • Total mice needed: (4 mice/treatment) (6 treatments) (3 experiments) 72 mice.
  • mice are inoculated with GFP-labeled bone marrow (BM)-derived cells and/or with transformed benign human or mouse cells. Tumor inoculations are performed on mice anesthetized with isofiuorane in a bell jar. The mice are placed in the jar which contains isofiuorane treated cotton balls inside a polypropylene centrifuge tube. During the procedure the mice are monitored by observing respiratory rate, movement, muscle relaxation, and lack of directed movement. After inoculation, mice are returned to their cages and monitored until they regain normal consciousness. [0054] 100 ul of PBS containing 5 X 10 5 cells is administered to each mouse.
  • BM bone marrow
  • Athymic nude mice receive 308 cells, BM cells, or a PEG-treated mixture of BM cells and 308 cells.
  • SCID mice receive DU145 cells, BM cells, or a PEG-treated mixture of BM cells and DU 145 cells.
  • Inoculations are administered subcutaneously or by tail vein injection. For those mice receiving tail vein infections, the mice are confined in a restraint box. After disinfection of the tail with alcohol, 2% xylacaine is applied as a topical anesthetic. No more than 200 ul of solution is injected into each mouse, using a 25-30 gauge needle.
  • the tails are sprayed with ethyl chloride, dipped in betadine, and removed with sterile scissors just above the necrotic area. The tail then is cauterized with silver nitrate to stop bleeding.
  • Tumor growth is monitored by caliper measurement o tumor dimensions twice weekly, and calculation of volume using the formula: Volume _+V 2 (length)(lengtth 2 ) Animals is sacrificed at 2, 3, and 4 weeks to monitor for the extent " of metastasis and the volume of tumor achieved.
  • Treatment groups for each method of injection - (6) 308 cells; BM cells; PEG-treated mixture of BM cells + 308 cells; DU145; BM cells, PEG treated DU145 and BM cell mixture.
  • mice Anesthetized with isofluorane in a bell jar.
  • the mice are placed in the jar which contains isofluorane treated cotton balls inside a polypropylene centrifuge tube.
  • the mice are monitored by observing respiratory rate, movement, muscle relaxation, and lack of directed movement.
  • mice are returned to their cages and monitored until they regain normal consciousness.
  • 100 ul of PBS containing 10 4 4Tl cells is administered injected into a mammary fat pad of 4 Balb/c mice.
  • the athymic nude mice receive 100 ul of PBS containing I X lO 6 308 10Gy5 cells.
  • the SCID mice receive 100 ul of PBS containing I X lO 6 PC-3M cells.
  • the experiment is performed with administration of the antibody to the CRCX4 receptor before, concurrently, and after inoculation of tumor cells.
  • 4Tl cells are injected into Balb/c mammary fat pads.
  • 308 10Gy5 are injected into tail veins of nude mice, and PC-3 M cells are injected into the tail veins of SCID mice.
  • mice receiving tail vein injections are confined in a restraint box during the injection.
  • no more than 200 ul of solution is injected into each mouse, using a 25-30 gauge needle. If the injections cause necrosis, the tails is sprayed with ethyl chloride, dipped in betadine, and removed with sterile scissors just above the necrotic area. The tail then is cauterized with silver nitrate to stop bleeding.
  • Animals are monitored for pre- or post-inoculated with a potential inhibitor of metastasis and assayed for alterations in tumor cell apoptosis, differentiation, inhibition of metastasis.
  • Tissue samples are submitted for histopathological analysis to detect alterations in progression or metastasis associated with the treatment.
  • the histopathological analysis should include comparison of tumor growth with time, relative numbers and sizes of metastases, histological characterization of the tumor tissue.
  • PC-3M is a human prostate carcinoma cell line.
  • 4Tl is a mouse mammary carcinoma cell line. Both were maintained and in DMEM medium supplemented with 10% FBS and Glutamax 1 (DMEM medium).
  • Antibodies Three ubiquitin antibodies were used. 14372 is a polyclonal antibody to ubiquitin. 10C2-2 and Mel-14 are both monoclonal antibodies to ubiquitin.
  • Procedure (1) A 6-well plate containing a sterile coverslip in each well was seeded with IxIO 6 cells/well in DMEM medium, and incubated overnight at 37 0 C and 5% CO 2 , in a humidified incubator (standard conditions). [0071] The next day, the confluent monolayer on the coverslip was scratched once with a pipette tip. The medium was aspirated and the wells were rinsed with 1 mL of DMEM medium. Each cell line was treated with three different concentrations of each antibody: 5 ⁇ g/mL/10 6 cells, 25 ⁇ g/mL/10 6 cells and lOO ⁇ g/mL/10 6 cells. The plates were incubated for 11 hours with the cells. Control cells were treated with DPBS.
  • coverslips were evaluated after incubation for closure of the scratches as a result of cell migration.
  • the coverslips were then fixed and stained with 1:1 methanohacetone for 5 minutes at - 20°C and then rinsed with DPBS. Coverslips were mounted on glass slides. Images were captured with Metacam software using a workstation composed of an Nikon TE2000 microscope at 4X magnification.
  • Cells A metastatic mouse mammary carcinoma cell line, 4Tl, was used to test the.ability of a ubiquitin antibody to inhibit metastasis. The cells were maintained in DMEM medium under the culture conditions described in the previous protocol.
  • Antibodies The monoclonal ubiquitin antibody, Mel- 14, was used.
  • Procedure 4Tl cells were transiently transfected with an expression vector for the enhanced green florescence protein (EGFP). Cells were harvested 48 hours after transfection and incubated with either ubiquitin antibody, Mel- 14, or a control antibody, Rat IgG2A, at the concentrations of 180 ⁇ g per 10 6 cells in DPBS for one hour. After incubation, 250,000 cells were injected into the tail vein of SCID mice in a total volume of 50 ⁇ L. One week later, the mice were sacrificed and their lungs were removed and fixed in 4% formalin. Examination for the presence of metastatic colonies was performed on whole flattened lungs with a Nikon Eclipse 600 microscope at 1OX magnification. The presence of EGFP positive cells in the lung indicated that metastasis has occurred. Results:
  • the methods of this invention may be used to inhibit tumor migration in a subject.
  • a vertebrate subject preferably a mammal, more preferably a human, is administered an amount of the compound effective to inhibit tumor cell migration.
  • the compound or pharmaceutically acceptable salt thereof is preferably administered in the form of a pharmaceutical composition.
  • Doses of the compounds preferably include pharmaceutical dosage units comprising an effective amount of the antibody or other agent.
  • an effective amount is meant an amount sufficient to achieve a steady state concentration in vivo which results in a measurable reduction in any relevant parameter of disease.
  • Monoclonal antibodies are now routinely used for therapy by infusion directly into the patient.
  • the antibody can be lyophilized and stored until reconstitution with either water or saline.
  • a dose of 4mg/kg body weight is a typical and safe human dosage for antibody-based therapies.
  • this is an effective dose of the breast cancer antibody therapy Herceptin.
  • a human patient is dosed at 4mg of a anti-ubiquitin antibody per kg body weight that is given intravenously.
  • compositions and treatment methods are useful for inhibiting cell migration (e.g., invasion or metastasis) in a subject having any disease or condition associated with undesired cell invasion, proliferation, metastasis.

Abstract

L'invention concerne des procédés pour modéliser la migration de cellules cancéreuses, cribler des médicaments destinés à agir sur la migration de cellules tumorales, et détecter le potentiel de migration de cellules tumorales en rapport avec la fusion d'une cellule souche de moelle osseuse avec une cellule génétiquement modifiée. Il a été démontré que les anticorps dirigés contre l'ubiquitine inhibent la migration de cellules tumorales.
EP06802407.4A 2005-08-25 2006-08-25 Modèle de carcinogenèse par fusion de cellules souches Not-in-force EP1924685B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11165870.4A EP2363146B1 (fr) 2005-08-25 2006-08-25 Procédé d'inhibition de la métastase dans une modèle de fusion de cellule souche de carcinogenèse

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71124905P 2005-08-25 2005-08-25
PCT/US2006/033366 WO2007025216A2 (fr) 2005-08-25 2006-08-25 Modele de carcinogenese par fusion de cellules souches

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP11165870.4A Division EP2363146B1 (fr) 2005-08-25 2006-08-25 Procédé d'inhibition de la métastase dans une modèle de fusion de cellule souche de carcinogenèse
EP11165870.4A Division-Into EP2363146B1 (fr) 2005-08-25 2006-08-25 Procédé d'inhibition de la métastase dans une modèle de fusion de cellule souche de carcinogenèse

Publications (3)

Publication Number Publication Date
EP1924685A2 true EP1924685A2 (fr) 2008-05-28
EP1924685A4 EP1924685A4 (fr) 2009-03-04
EP1924685B1 EP1924685B1 (fr) 2014-08-27

Family

ID=37772481

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11165870.4A Not-in-force EP2363146B1 (fr) 2005-08-25 2006-08-25 Procédé d'inhibition de la métastase dans une modèle de fusion de cellule souche de carcinogenèse
EP06802407.4A Not-in-force EP1924685B1 (fr) 2005-08-25 2006-08-25 Modèle de carcinogenèse par fusion de cellules souches

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP11165870.4A Not-in-force EP2363146B1 (fr) 2005-08-25 2006-08-25 Procédé d'inhibition de la métastase dans une modèle de fusion de cellule souche de carcinogenèse

Country Status (16)

Country Link
US (2) US8158126B2 (fr)
EP (2) EP2363146B1 (fr)
JP (2) JP5400381B2 (fr)
KR (2) KR101413048B1 (fr)
CN (2) CN103212071B (fr)
AU (2) AU2006282853B2 (fr)
BR (1) BRPI0615081A2 (fr)
CA (2) CA2620616C (fr)
ES (2) ES2523857T3 (fr)
HK (1) HK1161976A1 (fr)
HU (1) HUE025948T2 (fr)
IL (2) IL189674A (fr)
RU (1) RU2404805C2 (fr)
SG (1) SG152229A1 (fr)
WO (1) WO2007025216A2 (fr)
ZA (1) ZA200802512B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207227B2 (en) 1999-04-05 2012-06-26 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US8431736B2 (en) 2005-09-19 2013-04-30 Emisphere Technologies, Inc. Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2620616C (fr) * 2005-08-25 2016-06-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Modele de carcinogenese par fusion de cellules souches
US20120295344A1 (en) * 2006-08-25 2012-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Stem Cell Fusion Model of Carcinogenesis
ES2535856T3 (es) 2005-12-15 2015-05-18 Genentech, Inc. Métodos y composiciones para dirigirse a la poliubiquitina
ES2414804T3 (es) 2008-01-18 2013-07-22 Genentech, Inc. Métodos y composiciones que se dirigen a la poliubiquitina
CN101760452B (zh) * 2008-11-18 2012-12-19 中国科学院上海生命科学研究院 一种胚胎干细胞和肿瘤细胞的杂合细胞系及其构建方法
US8178307B2 (en) * 2009-09-02 2012-05-15 National Tsing Hua University Methods and compositions for detection of lethal cell and uses thereof
US8992919B2 (en) 2010-04-15 2015-03-31 Genentech, Inc. Anti-polyubiquitin antibodies and methods of use
CN103347521B (zh) 2010-12-06 2018-05-25 全球癌症治疗有限责任公司 用于治疗癌症的使用化疗和免疫治疗的代谢靶向癌细胞的方法
BR112014002716A2 (pt) 2011-08-05 2017-06-13 Genentech Inc anticorpos anti-poliubiquitina e métodos de uso
CN110391025A (zh) * 2018-04-19 2019-10-29 清华大学 一种面向宏微观多维度胃癌早期风险评估的人工智能建模方法
US11052041B1 (en) 2020-10-01 2021-07-06 King Abdulaziz University Nanotechnology-based nostril drops for relief of respiratory ailments

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004093646A2 (fr) * 2003-04-18 2004-11-04 University Of Massachusetts Pronostic, diagnostic et traitement de moelle osseuse derivee de cellules souches associees au cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0462111A4 (en) * 1988-12-23 1992-07-08 The Board Of Trustees Of The Leland Stanford Junior University Homing sequences and their uses
US6007816A (en) * 1989-03-17 1999-12-28 Fred Hutchinson Cancer Research Center Methods of using CD44-specific antibodies
WO1994021294A1 (fr) * 1993-03-19 1994-09-29 Bigner Darell D Procede de traitement de tumeurs a l'aide d'anticorps
CA2235245A1 (fr) 1995-10-17 1997-04-24 Dovetail Technologies, Inc Stimulants a faible poids moleculaire des cellules de la moelle osseuse et du systeme immunitaire
IL148351A0 (en) * 1999-08-25 2002-09-12 Altarex Inc Therapeutic immune condition compositions and methods
CN1302102C (zh) * 2003-12-29 2007-02-28 中国医学科学院血液学研究所 通过扩增巨核祖细胞和成熟巨核细胞制备巨核细胞制剂的方法及用途
US20060033366A1 (en) 2004-08-11 2006-02-16 Jeffrey Vernon M Headrest display device
WO2007014049A2 (fr) * 2005-07-22 2007-02-01 The Regents Of The University Of California Compositions d'heparine inhibitrices de la selectine
CA2620616C (fr) * 2005-08-25 2016-06-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Modele de carcinogenese par fusion de cellules souches

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004093646A2 (fr) * 2003-04-18 2004-11-04 University Of Massachusetts Pronostic, diagnostic et traitement de moelle osseuse derivee de cellules souches associees au cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HE X ET AL: "A stem cell fusion model of carcinogenesis" JOURNAL OF EXPERIMENTAL THERAPEUTICS AND ONCOLOGY, RAPID SCIENCE PUBLISHERS, LONDON, GB, vol. 5, no. 2, 25 October 2005 (2005-10-25), pages 101-109, XP009109511 ISSN: 1359-4117 *
LARIZZA L ET AL: "Suggestive evidence that the highly metastatic variant ESb of the T-cell lymphoma Eb is derived from spontaneous fusion with a host macrophage." INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 15 NOV 1984, vol. 34, no. 5, 15 November 1984 (1984-11-15), pages 699-707, XP002507584 ISSN: 0020-7136 *
See also references of WO2007025216A2 *
TERADA NAOHIRO ET AL: "Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion." NATURE 4 APR 2002, vol. 416, no. 6880, 4 April 2002 (2002-04-04), pages 542-545, XP002509715 ISSN: 0028-0836 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207227B2 (en) 1999-04-05 2012-06-26 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US8658695B2 (en) 1999-04-05 2014-02-25 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US8431736B2 (en) 2005-09-19 2013-04-30 Emisphere Technologies, Inc. Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid
US9238074B2 (en) 2005-09-19 2016-01-19 Emisphere Technologies, Inc. Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid

Also Published As

Publication number Publication date
CA2808168C (fr) 2018-06-12
US20090016961A1 (en) 2009-01-15
EP2363146B1 (fr) 2015-06-24
IL222468A (en) 2015-10-29
JP2009505664A (ja) 2009-02-12
WO2007025216A3 (fr) 2007-07-05
ZA200802512B (en) 2009-01-28
CN101273124B (zh) 2013-05-08
SG152229A1 (en) 2009-05-29
KR20080048499A (ko) 2008-06-02
HUE025948T2 (en) 2016-05-30
ES2552101T3 (es) 2015-11-25
CN103212071A (zh) 2013-07-24
CN101273124A (zh) 2008-09-24
AU2011201605B2 (en) 2012-12-20
KR101413048B1 (ko) 2014-06-30
RU2404805C2 (ru) 2010-11-27
JP5400381B2 (ja) 2014-01-29
BRPI0615081A2 (pt) 2011-05-03
IL189674A (en) 2012-10-31
ES2523857T3 (es) 2014-12-02
EP1924685B1 (fr) 2014-08-27
EP1924685A4 (fr) 2009-03-04
CA2808168A1 (fr) 2007-03-01
CA2620616C (fr) 2016-06-14
RU2008111144A (ru) 2009-09-27
JP5597171B2 (ja) 2014-10-01
CA2620616A1 (fr) 2007-03-01
HK1161976A1 (en) 2012-08-17
US8158126B2 (en) 2012-04-17
AU2011201605A1 (en) 2011-04-28
WO2007025216A2 (fr) 2007-03-01
US8758755B2 (en) 2014-06-24
KR20130020738A (ko) 2013-02-27
IL189674A0 (en) 2008-06-05
JP2011225613A (ja) 2011-11-10
AU2006282853A1 (en) 2007-03-01
US20120201808A1 (en) 2012-08-09
KR101413055B1 (ko) 2014-07-02
AU2006282853B2 (en) 2011-01-20
EP2363146A1 (fr) 2011-09-07
CN103212071B (zh) 2017-12-12

Similar Documents

Publication Publication Date Title
US8758755B2 (en) Stem cell fusion model of carcinogenesis
Wei et al. FOXF1 mediates mesenchymal stem cell fusion-induced reprogramming of lung cancer cells
CN110172442B (zh) 一种人诱导多潜能干细胞、构建方法及其用途
US20140308297A1 (en) Stem Cell Fusion Model of Carcinogenesis
Goncalves et al. Bioactive factors secreted from mesenchymal stromal cells protect the intestines from experimental colitis in a three-dimensional culture
Mok et al. Human mesenchymal stromal cells could deliver erythropoietin and migrate to the basal layer of hair shaft when subcutaneously implanted in a murine model
Azzarone et al. Human fibroblasts from cancer patients: lifespan and transformed phenotype in vitro and role of mesenchyme in vivo
Wang et al. Fetal human neural progenitors can be the target for tumor transformation
US20200108091A1 (en) Gut-protective effect of rig-1/mavs and sting activation
KR20230087559A (ko) 정상 핵형을 갖는 신규한 nr1 es-유래 신경 줄기세포 및 이의 용도
CN117050157A (zh) 异体共生年轻化因子及其在延缓机体衰老中的应用

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080305

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20090202

17Q First examination report despatched

Effective date: 20090513

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602006042867

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C12N0005080000

Ipc: C12N0005095000

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/095 20100101AFI20140116BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140312

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 684560

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006042867

Country of ref document: DE

Effective date: 20141002

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: FREI PATENTANWALTSBUERO AG, CH

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2523857

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20141202

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 684560

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140827

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: SE

Ref legal event code: RPOT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140827

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141128

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140827

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141229

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140827

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141227

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140827

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140827

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140827

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140827

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140827

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140827

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006042867

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140827

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20150528

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E023732

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140827

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140827

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150825

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140827

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20180827

Year of fee payment: 13

Ref country code: DE

Payment date: 20180829

Year of fee payment: 13

Ref country code: NL

Payment date: 20180826

Year of fee payment: 13

Ref country code: IT

Payment date: 20180822

Year of fee payment: 13

Ref country code: FR

Payment date: 20180827

Year of fee payment: 13

Ref country code: ES

Payment date: 20180904

Year of fee payment: 13

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: POSTFACH, 8032 ZUERICH (CH)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20180827

Year of fee payment: 13

Ref country code: GB

Payment date: 20180828

Year of fee payment: 13

Ref country code: CH

Payment date: 20180905

Year of fee payment: 13

Ref country code: SE

Payment date: 20180829

Year of fee payment: 13

Ref country code: CZ

Payment date: 20180803

Year of fee payment: 13

Ref country code: HU

Payment date: 20180813

Year of fee payment: 13

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602006042867

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20190901

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20190825

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190826

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190831

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190831

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190825

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190831

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190901

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200303

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190825

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190825

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190831

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190825

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20210108

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190826